Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.
Coulter Partners was delighted to partner once again with innovative nanoparticle medicine enabling company, Nanoform to secure the appointment of Sally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market.
• Mogrify platform recognized as having potential to transform future development of new medicines at prestigious awards ceremony
• Mogrify Chair receives Lifetime Achievement Award for contributions to biologics discovery and development
Global Life Sciences search specialist, Coulter Partners is delighted to announce the opening of a new office in the Belgian capital and six key appointments. Penny Sadler strengthens the company’s rapidly growing Medtech expertise as Client Partner in Brussels, while Dr Nanna Soni (PhD DIC) is appointed Director in London to the R&D centre of expertise. Please see Press Release for full details.
A new report released today by BioBeat entitled “50 Movers & Shakers in BioBusiness 2019” includes five women from organisations based at Stevenage Bioscience Catalyst (SBC) as well as two Board members. The report highlights the top female talent in the pharma and biotech sectors within the UK.
Cambridge, UK, 31st October 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, was named ‘The One to Watch’ at the Cambridge Independent Science and Technology Awards 2019. The award recognizes the potential of their proprietary direct cellular conversion technology, enabling any mature adult cell to be transformed into any other, without going through a pluripotent stem cell or progenitor cell-state.
Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the Company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.